• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

32.93 +0.76 (+2.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,959,751
Open 32.00
Bid (Size) 33.03 (100)
Ask (Size) 34.00 (700)
Prev. Close 32.17
Today's Range 31.37 - 33.34
52wk Range 9.900 - 34.29
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 08, 2026
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Prepares for Transformational 2026
January 06, 2026
From Viridian Therapeutics, Inc.
Via Business Wire

Performance

YTD
+7.3%
+7.3%
1 Month
+2.0%
+2.0%
3 Month
+48.6%
+48.6%
6 Month
+90.6%
+90.6%
1 Year
+75.5%
+75.5%

More News

Read More
News headline image
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
January 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
December 22, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup ↗
December 18, 2025
Via Chartmill
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 05, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
November 03, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
October 21, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Proposed Underwritten Public Offering
October 21, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts ↗
October 21, 2025
Via Benzinga
News headline image
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
October 20, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
September 29, 2025
Via Benzinga
News headline image
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
September 15, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results ↗
August 07, 2025
Via Benzinga
News headline image
Viridian (VRDN) Q2 Net Loss Widens 55% ↗
August 06, 2025
Via The Motley Fool
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 06, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
July 30, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2025
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
May 20, 2025
From Viridian Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
What is the current price of Viridian Therapeutics, Inc. - Common Stock?
The current price of Viridian Therapeutics, Inc. - Common Stock is 32.93
When was Viridian Therapeutics, Inc. - Common Stock last traded?
The last trade of Viridian Therapeutics, Inc. - Common Stock was at 01/23/26 04:00 PM ET
What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 315.71M
How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
Viridian Therapeutics, Inc. - Common Stock has 316M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap